[Bisphosphonate for GnRH therapy]
other
public-domain-us
AI-generated summary
Bisphosphonates, particularly pamidronate, effectively inhibit bone resorption and osteopenia induced by GnRH therapy, which lowers sex steroids for disease treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
GnRH therapy is useful for the treatment of various diseases, such as prostate cancer, endometriosis, uterine leiomyoma, based on its reduction of sex steroids. However, it causes osteopenia with high bone turnover in the mechanism similar with ovariectomy or castration. Bisphosphonate potently inhibits bone resorption, which subsequently inhibits elevated metabolic bone markers and osteopenia by GnRH therapy. The intravenous administration of pamidronate markedly inhibited osteopenia induced by GnRH therapy in some reports, but further study is necessary about the usage of bisphosphonate for osteopenia accompanied by GnRH therapy.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-20T09:27:46.357103+00:00
- pubmed
- last seen: 2026-05-13T22:15:41.664291+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine